Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

91.950
+4.8005.51%
Volume:23.31M
Turnover:2.14B
Market Cap:157.60B
PE:-1.44K
High:93.200
Open:88.000
Low:87.900
Close:87.150
52wk High:109.100
52wk Low:28.650
Shares:1.71B
HK Float Shares:1.71B
Volume Ratio:2.52
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.064
ROE:8.43%
ROA:2.65%
PB:9.98
PE(LYR):-1,443.94
PS:12.60

Loading ...

Active Southbound Stock Connect Trading on November 13

Stock News
·
Yesterday

JD Health International Reports Strategic Partnerships and New Drug Launches in Q3 2025

Reuters
·
Yesterday

HK Movers | Biomedical Stocks Jump With BeOne Medicines and Biocytogen up 7%

Tiger Newspress
·
Yesterday

Innovent Biologics (SEHK:1801) Valuation in Focus After Promising Early Data for Novel Hypertension RNAi Therapy

Simply Wall St.
·
Yesterday

CMB International: Healthcare Sector Favors Stable Strategies, Opportunities in Undervalued Stocks

Stock News
·
Nov 10

Innovent Biologics Reports Positive Phase 1 Results for Hypertension siRNA Drug IBI3016

Reuters
·
Nov 10

Zhongtai International: Breakthroughs in Overseas Expansion of Innovative Drugs, Rational Drug Pricing Policies Expected; Key Recommendations Include HANSOH PHARMA (03692) and INNOVENT BIO (01801)

Stock News
·
Nov 06

Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting

Reuters
·
Nov 05

3 Asian Stocks Estimated To Be Trading At Discounts Up To 39.2%

Simply Wall St.
·
Nov 03

Innovent Biologics (SEHK:1801) Valuation Check After 40% Product Revenue Growth and Mazdutide Milestone

Simply Wall St.
·
Nov 03

How Surging Revenue and Mazdutide’s Phase 3 Success at Innovent Biologics (SEHK:1801) Has Changed Its Investment Story

Simply Wall St.
·
Nov 01

HK Stock Movement | INNOVENT BIO (01801) Rises Over 4% as Q3 Total Product Revenue Grows ~40% YoY

Stock News
·
Oct 31

Innovent Biologics, Inc. (1801) Announces Q3 2025 Revenue Update

Bulletin Express
·
Oct 30

Southbound Stock Connect Active Trading Highlights | October 30

Stock News
·
Oct 30

Innovent Biologics Product Revenue Surges 40% to Over RMB3.3 Billion in Q3 2025

Reuters
·
Oct 30

Innovent Biologics - Q3 2025 Total Product Revenue Exceeds RMB3.3 Bln

THOMSON REUTERS
·
Oct 30

INNOVENT BIO's Qian Lei Targets RMB 20 Billion Revenue by 2027, Plans Deeper Collaboration with JD HEALTH

Deep News
·
Oct 30

Caitong Securities: Phosphoramidite Monomer Demand to Boom, Companies in MNC Pharma Supply Chains Set to Benefit

Stock News
·
Oct 29

Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk

Dow Jones
·
Oct 27

Innovent's Mazdutide Shows Superiority in Glycemic Control With Weight Loss Over Semaglutide in a Head-to-Head Phase 3 Clinical Trial Dreams-3

THOMSON REUTERS
·
Oct 27